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180 LETTERS TO THE EDITORproduct in Ireland. Following its launch in February 1998,
we estimate in excess of 10000 patient years experience has
been gained without any untoward experiences being
reported. This represents the greatest cumulative experience
obtained to date for any BDP-HFA product and is
arguably the strongest and most meaningful evaluation of
such a product.
V. L. PERRIN AND D. W. FAKES
Norton Healthcare Ltd.,
London, U.K.
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1997; 51: 11–15.Re: inhaled beclomethasone (BDP)
with non-CFC propellent (HFA 134a)
is equivalent to BDP-CFC for the
treatment of asthma (Respir Med 1999;
93:245±251)In this journal Milanowski and co-workers published their
results of an equivalence trial comparing a HFA- and CFC-
BDP formulation (1). Their intention was to show that the
recently developed HFA-formulation is equivalent to the
older CFC one. The conclusion was that both formulations
were equivalent and a ‘change-over of patients straight-
forward’. A number of reasons render this conclusion of
equivalence, however, questionable.
This study based the equivalence claim on reporting a
lack of statistically significant dierences between two
preparations. This approach has become known as the so-
called power approach. In this approach, a priori, one
defines a maximal allowable dierence between the two
preparations. Subsequently one calculates a sample size
enabling the researcher to find that dierence. When the
study evaluation does not report any significant dierences,
the actual dierence between the two preparations must
have been smaller than the predefined critical (and
detectable) one. The conclusion therefore is that the actual
dierence between the two is smaller that the critical one
and equivalence can be claimed. However, the sample size
calculation (which is pivotal) is always based on retro-
spective data (mean and standard deviation), while thesedata can dier from the actual in the selective sample. So it
is possible that the standard deviation in the sample is
larger than in the retrospective data. When that happens,
the study will by definition result in no significant
dierences: the study is under-powered due to the larger
standard deviation (2).
When we follow this approach based on the data of the
low dose study in Table 3 of the publication, we can read
a mean FEV1 of 25+08 l for the reference CFC-BDP
formulation. So with an acceptable dierence of 02 l, the
lowest test HFA-BDP may be 23 l. Sample size calculation
with a standard deviation of 08 gives us a size per group of
338. A standard deviation of 0305, together with the other
data, would lead to the cited sample size of 50 per group.
We therefore ask ourselves whether this study was under-
powered and could not but result in non-significant
dierences, due to an incorrect estimate of the standard
deviation.
The power approach was put out of use much for the
above reason. The current approach of the two one-sided t-
test does not suer from the drawback of under-powered
studies. It is designed in such a way that an under-powered
study always leads to a conclusion of inequivalence. This
approach is based on a null hypothesis of inequivalence and
an alternative one of equivalence. To claim equivalence one
must reject inequivalence, which in statistical terms means
‘significant dierences’. It is easy to see that under-powered
study will never be able to reject the null hypothesis of
inequivalence. A study must be suciently large to reject
inequivalence and accept equivalence. In this way it is
impossible to market inequivalent preparations as result of
a flawed power approach study. The patient risk to use
inequivalent product is significantly reduced after imple-
mentation of the two one-sided t-test.
Now following the two one sided t-test approach and
again assuming that the maximal allowable dierence is 02
l, the dierence between the two preparations is 01 l with a
standard deviation of 0.8, the sample size per group would
be 1097!
The next point is the choice of a FEV1 dierence of 02 l
as the maximal allowable dierence. The authors thereby
state that the mean FEV1 in the HFA-group could be
25702=23 l and still be acceptable. A value lower than
23 l however would mean that the improvement in that
group would be very low: an increase from 22 to 23 l
would be sucient to claim non-significant dierences. In
other words, while the CFC-group improved 03, an
improvement of a mere 01 l in the HFA-group would be
sucient to claim equivalence. We feel that such a large
dierence between the improvements is not acceptable.
To conclude we feel that the approach taken by the
authors does not allow the conclusion of equivalence and
would ask them to elaborate on the starting points of their
sample size calculations.
P. ZANEN
Dept. Pulmonary Diseases,
University Hospital Utrecht,
The Netherlands
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Response to letter of Dr Zanen re:
paper by Milanowski et al. (Respir
Med 1999; 93: 245±251)We thank Dr Zanen for his reasoned statistical comments
on the studies (1,2). However, the aim of the two studies
was to demonstrate therapeutic equivalence between the
BDP-CFC and BDP-HFA inhalers based on meaningful
clinical dierences in everyday practice. Unfortunately, Dr
Zanen’s assumption that equivalence was based on a lack of
statistically significant dierences between the two prepara-
tions is incorrect given that the conclusions of equivalence
were derived from comparisons of confidence intervals for
the between-treatment dierence and an acceptable range
considered to be clinically equivalent.
The significant and equivalent improvements in lung
function and asthma symptoms seen with both BDP-CFC
and BDP-HFA in these studies are entirely consistent with
the literature on similar inhaled steroid studies. Minor
numerical dierences in lung function indices and standard
deviations between populations are unlikely to matter in
clinical practice, as has been borne out by successful
transfer of asthma patients from the BPD-CFC to the
BDP-HFA inhaler on a 1:1 dose basis since introduction of
the latter product to the market in Ireland 18 months ago.
We reiterate our belief that the sample sizes chosen in
these studies were based on clinically relevant dierences
and that the products are indeed equivalent in both
meaningful statistical terms and in clinical practice.
V. L. PERRIN, D. W. FAKES AND
D. UNDERWOOD
Norton Healthcare Ltd and Statwood Partnership
References
1. Milanowski J, Qualtrough J, Perrin V. Inhaled beclo-
methasone (BDP) with non-CFC propellant (HFA 134a)
is equivalent to BDP-CFC for the treatment of asthma.
Respir Med 1999; 93: 245–251.
2. Schuirmann DJ. A comparison of the two one-sided
tests procedure and the power approach for assessing theequivalence of average bioavailability. J Pharmacokin
Biopharm 1987; 15: 657–680.Dear Editor
Inhaled beclomethasone (BDP) with
non-CFC propellant (HFA-134a) is
equivalent to BDP-CFC for the
treatment of asthma: Milanowski
et al. (Respir Med 1999; 93: 245±251)I read with interest the paper from Milanowski et al. on the
equivalence of BDP-HFA to BDP-CFC. This is based on
two studies, one low dose (400 mcg day71 BDP) and one
high dose (2000 mcg day71). The results of these studies I
think should be viewed with caution but open up some
interesting areas of debate.
The statistical analysis for both studies was based on
testing for dierence. This was defined as a dierence in
mean pre-dose FEV1 of 402 l. The results clearly show
that the 90% confidence interval for the high dose study
(7034–05) lies outside +02 l. Similarly for the low dose
study the 90% confidence interval is (7014–035), again
lying outside the upper end of the pre-defined +02 l.
It is stated that the total number of patients needed to
detect a statistical dierence with 90% power using 90%
confidence intervals was 100. The standard deviation for
FEV1 in both studies was around 08 l. To detect
equivalence or dierence, based on these assumptions, the
total number of patients needed would be 275 and 338 per
treatment group respectively, greatly in excess of 100. It
would therefore appear that these studies are both under-
powered and inconclusive. Consequently the interpretation
by Milanowski et al. that BDP-CFC and BDP-HFA
(Norton Healthcare Ltd, U.K.) are clinically and statisti-
cally equivalent should be viewed with caution.
The dosing schedule of qds dosing is not in line with the
British Asthma Guidelines and would have led to poor
compliance in some subjects. The rationale behind this
schedule needs to be justified. In the high dose study a very
wide-ranging group of patients (taking 800–2000 mcg day
BDP71) were randomized to 2000 mcg of either BDP-HFA
or BDP-CFC patients. This wide variability may account
for the large confidence intervals seen in this study, but
underlies the need to conduct robustly designed ecacy and
safety studies as well as dose response studies.
The study also considers safety, as measured by adverse
events and am plasma cortisol. Morning plasma cortisol is
a very variable measure and studies using 24 h urinary free
cortisol would be a more helpful measure to define any
clinically relevant dierence between the two formulations.
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